Vaxart Reports News Data of VXA-CoV2-1 (Oral COVID-19 Vaccine) in P-I Trial Against Other Coronaviruses

 Vaxart Reports News Data of VXA-CoV2-1 (Oral COVID-19 Vaccine) in P-I Trial Against Other Coronaviruses

Shots:

  • The company reported the new data from the P-I COVID-19 trial evaluating the safety & immunogenicity of VXA-CoV2-1 suggesting that vaccine triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins and has broad cross-coronavirus activity
  • The results showed higher CD8+ T-cell responses as measured by IFN-g and TNF-a induction than the patients vaccinated with Pfizer and Moderna’s vaccines
  • The Vaxart vaccine candidate elicited a T-cell response against SARS-Cov-2, as well as showed cross-reactivity against diverse endemic coronaviruses such as 229E, NL63, HKU1, and OC43

Click here to­ read full press release/ article | Ref: GLOBE NEWSWIRE | Image: Vaxart

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post